Drug Trial Radar · NCT00985660
Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg
Last checked: Nov 19, 2026Latest source record: Sep 28, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jun 2007
Primary completion
Jul 2007
Study completion Jul 2007
Sponsor
- Lead sponsor
- Mylan Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 28, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy adult subjects under fasting conditions.
Conditions
- Healthy
Interventions
Nisoldipine Extended-release Tablets, 30 mgDrug
1 x 30 mg Tablet under fasting conditions
Sular® Extended Release Tablets, 30 mgDrug
1 x 30 mg Tablet under fasting conditions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration time curveTime frame: Serial plasma samples collected for up to 72 hours post-dose
- Maximum Plasma ConcentrationTime frame: Serial plasma samples collected up to 72 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRACS Institute Ltd.
Fargo, North Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.